Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- 7 August 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 392 (10148), 650-661
- https://doi.org/10.1016/s0140-6736(18)31713-6
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The global burden of psoriatic skin diseaseBritish Journal of Dermatology, 2015
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJournal of Allergy and Clinical Immunology, 2015
- PASI90 response: the new standard in therapeutic efficacy for psoriasisJournal of the European Academy of Dermatology and Venereology, 2014
- The IL-23–IL-17 immune axis: from mechanisms to therapeutic testingNature Reviews Immunology, 2014
- Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyJournal of the American Academy of Dermatology, 2014
- Psoriasis Severity and the Prevalence of Major Medical ComorbidityJAMA Dermatology, 2013
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- Geoepidemiology and environmental factors of psoriasis and psoriatic arthritisJournal of Autoimmunity, 2010
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008